ALBERT KIM

Vice President, Clinical Research Head
Pfizer
New Zealand

Scientist Toxicology
Biography

Albert Kim, MD, PhD, is Vice President and Clinical Research Head for the Cardiovascular and Metabolic Disease Research Unit, he is an accomplished physician-scientist with broad expertise in cardiovascular disease, translational medicine, and drug development. Dr. Kim joined the Pfizer Cardiovasular and Metabolic Diseases Research Unit in 2013 and has served in multiple roles over the past three years leading early asset teams and contributing as a core member of the cardiovascular therapeutic area strategy team. Most recently, he was a co-Global Clinical Lead for the bococizumab Phase III program. In addition to project leadership experience, he has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the US Food and Drug Administration in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. 

Research Intrest

 Clinical Research